Dow Jones

52 900,07

1,14%

Germany 40

Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.

Accueil
Investir
Actions
Etats-Unis
USOTC
Bayer Aktiengesellschaft (QX) (BAYRY)
Bayer Aktiengesellschaft (QX) (BAYRY) Actualités

Bayer Aktiengesellschaft (QX) (BAYRY)

15,185

1,34

(9,64%)

Fermé 03 Juillet 10:00PM

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Luke Bryan and One A Day® Launch Limited Edition Multivitamin Bottles Available Only at Walmart

One A Day®, the multivitamin and supplement brand from Bayer, has partnered with country superstar and five...

Bayer Group to Consolidate U.S. Glyphosate Business Into Distinct Entity Operating as Ruveon

Advances key component of Crop Science division’s Five-Year Framework strategy Reinforces commitment to delivering trusted Roundup® brands and...

Bayer and Iambic Collaborate to Advance Drug Discovery with AI

Collaboration focuses on small molecule discovery Bayer to leverage Iambic’s AI platform to address hard-to-drug targets Collaboration will...

BAYER ACCUEILLE KACY PERRY À TITRE DE NOUVELLE CHEF NATIONALE DE CROP SCIENCE CANADA

La division Crop Science de Bayer a annoncé que Kacy Perry a été nommée chef nationale de Crop Science Canada. Elle entrera en fonction le 1er...

Bayer Completes Acquisition of Perfuse Therapeutics

Bayer today announced the completion of the acquisition of Perfuse Therapeutics, Inc. As a result, Perfuse Therapeutics will now be fully...

Aleve® Launches its Project DIY Campaign with HGTV Stars Dave & Jenny Marrs to Highlight Hardworking Hobbyists and Long-Lasting Pain Relief

Key Facts Campaign: Project DIY is a new campaign under Aleve’s recently launched Feel Aleve® platform...

Bayer’s AMBELVIST® (gadoquatrane) Receives FDA Approval for Contrast-Enhanced MRI to Detect and Visualize Lesions with Abnormal Vascularity in the Central Nervous System and Non-CNS Body Regions

Key Facts: Bayer’s AMBELVIST® (gadoquatrane) becomes the lowest-dose macrocyclic gadolinium (Gd)-based contrast agent (mGBCA) approved in the...

Dr. Jost Reinhard Appointed President of Bayer’s Radiology Business

Bayer today announced that Dr. Jost Reinhard has been appointed President of the Radiology business within Bayer’s Pharmaceuticals Division...

Bayer Announces Global Consumer Health Leadership Changes to Accelerate Growth

Bayer today announced leadership changes within its Consumer Health division to accelerate growth, strengthen commercial execution, and further...

Phase III FIND‑CKD Results Show Bayer’s KERENDIA® (finerenone) Improved eGFR Slope and Reduced Risk of a Composite Kidney-Cardiovascular Outcome in Adults with Non‑Diabetic Chronic Kidney Disease

Investigational results from FIND-CKD provide full efficacy and safety data and is the fifth consecutive Phase III clinical trial where KERENDIA...

Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026

Presentations also include the INFINITY pooled analysis of KERENDIA® (finerenone) across diabetic and non-diabetic chronic kidney disease. Bayer...

ASCO 2026: Bayer Shares New Findings for NUBEQA® (darolutamide) Regarding Cognitive Decline in Men with Advanced Prostate Cancer Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial

Phase II ARACOG (AFT-47) head-to-head trial met its primary endpoint, with patients treated with NUBEQA® (darolutamide) showing a decline in...

ASCO 2026: Bayer to Present New Data Across Oncology Portfolio

Primary results from the Phase II ARACOG (AFT-47) head-to-head trial evaluating NUBEQA® (darolutamide) versus enzalutamide in men with...

Bayer’s KERENDIA® (finerenone) Granted Priority Review of Supplemental New Drug Application by U.S. FDA for Treatment of Adults with Type 1 Diabetes and Chronic Kidney Disease

If approved for this investigational new use, KERENDIA® (finerenone), a non-steroidal mineralocorticoid antagonist (MRA), would be the first MRA...

Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack

KEY FACTS: Regulatory submission is based on positive results from the Phase III OCEANIC-STROKE study OCEANIC-STROKE met the primary efficacy...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

USOTC

BAYRY

Bayer Aktiengesellschaft (QX)

Favorit Hold AD Sofia

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

Vous avez déjà un compte? Connexion

Vous n'avez pas de compte ? Inscription

En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Bayer Aktiengesellschaft (QX) (BAYRY)

Outils de qualité professionnelle, pour des investisseurs individuels.